# Sensus Healthcare, Inc.: financial statements, quarterly

SRTS · Nasdaq · CIK 1494891 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/srts.md) · [Financials](/companies/srts/financials.md) · [Filings](/companies/srts/filings.md) · [Insiders](/companies/srts/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/srts/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.9](/filings/0001213900-24-098193.md) | [12.6 d](/filings/0001753926-25-000408.md) | [10.7](/filings/0001753926-25-000853.md) | [9.2](/filings/0001753926-25-001290.md) | [8.8](/filings/0001753926-25-001745.md) | [13.1 d](/filings/0001753926-26-000435.md) | [8.3](/filings/0001753926-25-000853.md) | [7.3](/filings/0001753926-25-001290.md) | [6.9](/filings/0001753926-25-001745.md) | [4.9 d](/filings/0001753926-26-000435.md) | [3.4](/filings/0001753926-26-000845.md) | [2.3](/filings/0001753926-26-001508.md) |
| Cost of revenue | $m | [1.9](/filings/0001213900-24-098193.md) | [4.7 d](/filings/0001753926-25-000408.md) | [4.0](/filings/0001753926-25-000853.md) | [3.8](/filings/0001213900-24-068165.md) | [3.6](/filings/0001213900-24-098193.md) | [6.0 d](/filings/0001753926-26-000435.md) | [4.0](/filings/0001753926-26-000845.md) | [4.4](/filings/0001753926-26-001508.md) | [4.2](/filings/0001753926-25-001745.md) | [3.0 d](/filings/0001753926-26-000435.md) | [2.4](/filings/0001753926-26-000845.md) | [1.5](/filings/0001753926-26-001508.md) |
| Gross profit | $m | [2.0](/filings/0001213900-24-098193.md) | [7.8 d](/filings/0001753926-25-000408.md) | [6.7](/filings/0001753926-25-000853.md) | [5.4](/filings/0001753926-25-001290.md) | [5.2](/filings/0001753926-25-001745.md) | [7.1 d](/filings/0001753926-26-000435.md) | [4.4](/filings/0001753926-26-000845.md) | [2.9](/filings/0001753926-26-001508.md) | [2.7](/filings/0001753926-25-001745.md) | [1.9 d](/filings/0001753926-26-000435.md) | [1.0](/filings/0001753926-26-000845.md) | [0.8](/filings/0001753926-26-001508.md) |
| Research and development | $m | [1.1](/filings/0001213900-24-098193.md) | [0.7 d](/filings/0001753926-25-000408.md) | [0.9](/filings/0001753926-25-000853.md) | [0.9](/filings/0001753926-25-001290.md) | [0.9](/filings/0001753926-25-001745.md) | [1.6 d](/filings/0001753926-26-000435.md) | [2.6](/filings/0001753926-26-000845.md) | [1.5](/filings/0001753926-26-001508.md) | [1.8](/filings/0001753926-25-001745.md) | [1.9 d](/filings/0001753926-26-000435.md) | [1.6](/filings/0001753926-26-000845.md) | [1.1](/filings/0001753926-26-001508.md) |
| Selling, general and administrative | $m | not reported | not reported | [1.6](/filings/0001753926-25-000853.md) | [1.6](/filings/0001753926-25-001290.md) | [1.6](/filings/0001753926-25-001745.md) | [2.4 d](/filings/0001753926-26-000435.md) | [2.2](/filings/0001753926-26-000845.md) | [2.0](/filings/0001753926-26-001508.md) | [1.9](/filings/0001753926-25-001745.md) | [1.8 d](/filings/0001753926-26-000435.md) | [2.0](/filings/0001753926-26-000845.md) | [1.8](/filings/0001753926-26-001508.md) |
| Operating income | $m | [(1.9)](/filings/0001213900-24-098193.md) | [5.6 d](/filings/0001753926-25-000408.md) | [2.9](/filings/0001753926-25-000853.md) | [2.0](/filings/0001753926-25-001290.md) | [1.5](/filings/0001753926-25-001745.md) | [1.7 d](/filings/0001753926-26-000435.md) | [(2.6)](/filings/0001753926-26-000845.md) | [(1.9)](/filings/0001753926-26-001508.md) | [(2.6)](/filings/0001753926-25-001745.md) | [(3.1) d](/filings/0001753926-26-000435.md) | [(4.4)](/filings/0001753926-26-000845.md) | [(3.2)](/filings/0001753926-26-001508.md) |
| Interest expense | $m | not reported | not reported | [(0.2)](/filings/0001753926-25-000853.md) | [(0.2)](/filings/0001753926-25-001290.md) | not reported | not reported | [(0.2)](/filings/0001753926-25-000853.md) | [(0.2)](/filings/0001753926-25-001290.md) | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.1)](/filings/0001213900-24-098193.md) | [1.6 d](/filings/0001753926-25-000408.md) | [0.8](/filings/0001753926-25-000853.md) | [0.6](/filings/0001753926-25-001290.md) | [0.6](/filings/0001753926-25-001745.md) | [0.4 d](/filings/0001753926-26-000435.md) | [0.1](/filings/0001753926-26-000845.md) | [(0.7)](/filings/0001753926-26-001508.md) | [(1.5)](/filings/0001753926-25-001745.md) | [0.2 d](/filings/0001753926-26-000435.md) | [(1.6)](/filings/0001753926-26-000845.md) | [5.7](/filings/0001753926-26-001508.md) |
| Net income | $m | [(1.5)](/filings/0001213900-24-098193.md) | [4.2 d](/filings/0001753926-25-000408.md) | [2.3](/filings/0001753926-25-001745.md) | [1.6](/filings/0001753926-25-001745.md) | [1.2](/filings/0001753926-25-001745.md) | [1.5 d](/filings/0001753926-26-000435.md) | [(2.6)](/filings/0001753926-26-001508.md) | [(1.0)](/filings/0001753926-26-001508.md) | [(0.9)](/filings/0001753926-25-001745.md) | [(3.2) d](/filings/0001753926-26-000435.md) | [(2.6)](/filings/0001753926-26-001508.md) | [(8.7)](/filings/0001753926-26-001508.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001213900-24-098193.md) | not reported | [0.14](/filings/0001753926-25-000853.md) | [0.10](/filings/0001753926-25-001290.md) | [0.07](/filings/0001753926-25-001745.md) | not reported | [(0.16)](/filings/0001753926-26-000845.md) | [(0.06)](/filings/0001753926-26-001508.md) | [(0.06)](/filings/0001753926-25-001745.md) | not reported | [(0.16)](/filings/0001753926-26-000845.md) | [(0.53)](/filings/0001753926-26-001508.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001213900-24-098193.md) | not reported | [0.14](/filings/0001753926-25-000853.md) | [0.10](/filings/0001753926-25-001290.md) | [0.07](/filings/0001753926-25-001745.md) | not reported | [(0.16)](/filings/0001753926-26-000845.md) | [(0.06)](/filings/0001753926-26-001508.md) | [(0.06)](/filings/0001753926-25-001745.md) | not reported | [(0.16)](/filings/0001753926-26-000845.md) | [(0.53)](/filings/0001753926-26-001508.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [20.5](/filings/0001213900-23-086237.md) | [23.1](/filings/0001753926-25-000408.md) | [14.7](/filings/0001213900-24-041605.md) | [19.0](/filings/0001213900-24-068165.md) | [22.6](/filings/0001213900-24-098193.md) | [22.1](/filings/0001753926-26-000435.md) | [19.1](/filings/0001753926-25-000853.md) | [22.2](/filings/0001753926-25-001290.md) | [24.5](/filings/0001753926-25-001745.md) | [22.1](/filings/0001753926-26-001508.md) | [18.3](/filings/0001753926-26-000845.md) | [15.2](/filings/0001753926-26-001508.md) |
| Current assets | $m | [45.9](/filings/0001213900-23-086237.md) | [49.5](/filings/0001753926-25-000408.md) | [53.9](/filings/0001213900-24-041605.md) | [54.5](/filings/0001213900-24-068165.md) | [54.8](/filings/0001213900-24-098193.md) | [56.7](/filings/0001753926-26-000435.md) | [54.2](/filings/0001753926-25-000853.md) | [52.2](/filings/0001753926-25-001290.md) | [50.2](/filings/0001753926-25-001745.md) | [45.9](/filings/0001753926-26-001508.md) | [42.6](/filings/0001753926-26-000845.md) | [37.7](/filings/0001753926-26-001508.md) |
| Total assets | $m | [50.5](/filings/0001213900-23-086237.md) | [53.7](/filings/0001753926-25-000408.md) | [57.3](/filings/0001213900-24-041605.md) | [58.2](/filings/0001213900-24-068165.md) | [59.9](/filings/0001213900-24-098193.md) | [62.2](/filings/0001753926-26-000435.md) | [60.2](/filings/0001753926-25-000853.md) | [58.9](/filings/0001753926-25-001290.md) | [58.3](/filings/0001753926-25-001745.md) | [53.0](/filings/0001753926-26-001508.md) | [51.5](/filings/0001753926-26-000845.md) | [41.3](/filings/0001753926-26-001508.md) |
| Current liabilities | $m | [5.2](/filings/0001213900-23-086237.md) | [4.2](/filings/0001753926-25-000408.md) | [5.5](/filings/0001213900-24-041605.md) | [4.7](/filings/0001213900-24-068165.md) | [5.2](/filings/0001213900-24-098193.md) | [5.9](/filings/0001753926-26-000435.md) | [6.7](/filings/0001753926-25-000853.md) | [6.4](/filings/0001753926-25-001290.md) | [6.8](/filings/0001753926-25-001745.md) | [4.7](/filings/0001753926-26-001508.md) | [5.9](/filings/0001753926-26-000845.md) | [4.3](/filings/0001753926-26-001508.md) |
| Total liabilities | $m | [6.0](/filings/0001213900-23-086237.md) | [4.9](/filings/0001753926-25-000408.md) | [6.1](/filings/0001213900-24-041605.md) | [5.3](/filings/0001213900-24-068165.md) | [5.7](/filings/0001213900-24-098193.md) | [6.3](/filings/0001753926-26-000435.md) | [7.2](/filings/0001753926-25-000853.md) | [6.8](/filings/0001753926-25-001290.md) | [7.1](/filings/0001753926-25-001745.md) | [4.9](/filings/0001753926-26-001508.md) | [6.0](/filings/0001753926-26-000845.md) | [4.4](/filings/0001753926-26-001508.md) |
| Shareholders' equity | $m | [44.6](/filings/0001213900-24-098193.md) | [48.8](/filings/0001753926-26-000435.md) | [51.2](/filings/0001753926-25-001745.md) | [52.9](/filings/0001753926-25-001745.md) | [54.1](/filings/0001753926-25-001745.md) | [55.8](/filings/0001753926-26-001508.md) | [53.0](/filings/0001753926-26-001508.md) | [52.1](/filings/0001753926-26-001508.md) | [51.2](/filings/0001753926-25-001745.md) | [48.1](/filings/0001753926-26-001508.md) | [45.5](/filings/0001753926-26-001508.md) | [36.9](/filings/0001753926-26-001508.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [442 d](/filings/0001213900-24-098193.md) | [2,668 d](/filings/0001753926-25-000408.md) | [(8,187)](/filings/0001753926-25-000853.md) | [4,230 d](/filings/0001753926-25-001290.md) | [3,953 d](/filings/0001753926-25-001745.md) | [(827) d](/filings/0001753926-26-000435.md) | [(2,677)](/filings/0001753926-26-000845.md) | [3,117 d](/filings/0001753926-26-001508.md) | [2,295 d](/filings/0001753926-25-001745.md) | [(2,207) d](/filings/0001753926-26-000435.md) | [(3,753)](/filings/0001753926-26-000845.md) | [(3,133) d](/filings/0001753926-26-001508.md) |
| Capital expenditure | $k | [11.0 d](/filings/0001213900-24-098193.md) | [0.0 d](/filings/0001753926-25-000408.md) | [233](/filings/0001753926-25-000853.md) | [3.0 d](/filings/0001753926-25-001290.md) | [337 d](/filings/0001753926-25-001745.md) | [(297) d](/filings/0001753926-26-000435.md) | [7.0](/filings/0001753926-26-000845.md) | [27.0 d](/filings/0001753926-26-001508.md) | [4.0 d](/filings/0001753926-25-001745.md) | [158 d](/filings/0001753926-26-000435.md) | [3.0](/filings/0001753926-26-000845.md) | [8.0 d](/filings/0001753926-26-001508.md) |
| Share repurchases | $k | not reported | [0.0 d](/filings/0001753926-25-000408.md) | not reported | not reported | not reported | not reported | [300](/filings/0001753926-26-000845.md) | [0.0 d](/filings/0001753926-26-001508.md) | [0.0 d](/filings/0001753926-25-001745.md) | [0.0 d](/filings/0001753926-26-000435.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [16.6](/filings/0001213900-23-086237.md) | [16.2](/filings/0001213900-24-041605.md) | [16.2](/filings/0001213900-24-068165.md) | [16.3](/filings/0001213900-24-098193.md) | [16.3](/filings/0001753926-25-000853.md) | [16.3](/filings/0001753926-25-001290.md) | [16.3](/filings/0001753926-25-001745.md) | [16.3](/filings/0001753926-26-000845.md) | [16.3](/filings/0001753926-26-001508.md) | [16.3](/filings/0001753926-25-001745.md) | [16.5](/filings/0001753926-26-000845.md) | [16.5](/filings/0001753926-26-001508.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,462,059 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001753926-26-001508.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.